Overview

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Status:
Active, not recruiting

Trial end date:
2022-10-16

Target enrollment:

Participant gender:

Summary

A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Osimertinib